317 articles
Triparanol
Triparanol (MER/29, metasqualene), a withdrawn Merrell hypolipidemic drug approved by FDA in 1960; first cholesterol-synthesis inhibitor, blocking desmosterol-to-cholesterol conversion, withdrawn 1962 for cataracts and falsified data.
UBT251
UBT251 is a long-acting triple agonist of the GLP-1, GIP, and glucagon receptors developed by United Biotechnology (TUL) and licensed to Novo Nordisk in March 2025; phase 2 trials in China showed up to 19.7% weight loss at 24 weeks in obesity and HbA1c reduction up to 2.16% in type 2 diabetes.
Urate-lowering therapy
Urate-lowering therapy (ULT) is drug treatment that reduces serum uric acid below the saturation point to dissolve crystals and prevent gout flares, using drugs such as allopurinol, febuxostat, and probenecid.
Urofollitropin
Urofollitropin (urinary FSH, u-FSH; brands Fertinex, Bravelle, Fostimon) is follicle-stimulating hormone purified from postmenopausal urine for ovarian stimulation; the highly purified 1993 form reached 95% FSH and enabled subcutaneous self-injection.
Utreglutide
Utreglutide (GL0034) is Sun Pharma's investigational once-weekly, G protein-biased GLP-1 receptor agonist for type 2 diabetes and obesity, structurally related to semaglutide, in phase 2 trials, unapproved.
Vadadustat
Vadadustat (VAFSEO, AKB-6548) is an oral HIF prolyl hydroxylase inhibitor approved in 2024 for anemia of chronic kidney disease in adults on dialysis, dosed 300 mg daily, noninferior to darbepoetin alfa in dialysis trials but not in non-dialysis CKD.
VCT220
VCT220 (CX11) is Vincentage Pharma's once-daily oral nonpeptide GLP-1 receptor agonist for obesity; its China Phase 3 trial showed 12.2–12.4% weight loss at 52 weeks, and its NDA was filed with China's CDE in July 2026.
Veverimer
Veverimer (TRC101) is Tricida's oral, non-absorbed hydrochloric acid binder for metabolic acidosis in CKD; it raised bicarbonate in early trials but the VALOR-CKD Phase 3 renal outcomes trial missed its primary endpoint.
Vipanatide? (维派那肽)
Vipanatide (维派那肽), officially Visepegenatide (维培那肽), code PB-119, trade name Paidakang, is PegBio's once-weekly PEGylated exenatide GLP-1 receptor agonist approved in China on November 14, 2025 for type 2 diabetes.
Voglibose
Voglibose (Basen, A-71100, AO-128) is a valiolamine-derived alpha-glucosidase inhibitor for postprandial hyperglycemia in type 2 diabetes; discovered in Japan in 1981, launched 1994 by Takeda, dosed 0.2 mg three times daily, not FDA-approved in the USA.
Vosoritide
Vosoritide (Voxzogo, BMN 111) is a 39-amino-acid C-type natriuretic peptide analog by BioMarin that binds NPR-B to counteract FGFR3 signaling, increasing linear growth in children with achondroplasia; approved from 2021 in the EU, US, Japan, and Australia.
WH007
WH007 is a Category 2.3 improved new drug of mulberry twig total alkaloids (桑枝总生物碱, SZ-A/Sangbo'en) for polycystic ovary syndrome, developed by Beijing Wehand-Bio with CAMS; NMPA IND approved December 2025, Phase II trial CTR20260897 (240 participants) started 2026.
Y-shape pegylated somatropin (怡培生长激素)
Y-shape pegylated somatropin (怡培生长激素, Inpegsomatropin, brand 益佩生/Pegpesen) is Xiamen Amoytop's once-weekly 40 kD Y-shaped branched PEG-modified growth hormone, NMPA-approved May 2025 for pediatric GHD, with phase 3 noninferior growth velocity and zero anti-drug antibodies versus daily rhGH.
YS2302018
YS2302018 is CSPC Pharmaceutical's preclinical oral small-molecule lipoprotein(a) inhibitor, discovered by its AI drug design platform and exclusively licensed to AstraZeneca in October 2024 for $100 million upfront plus up to $1.92 billion in milestones.
Zovaglutide
Zovaglutide (ZT002) is an investigational once-monthly GLP-1 receptor agonist peptide injection by Beijing QL Biopharmaceutical for obesity and type 2 diabetes, in phase 3 (HORIZON-1) in China, distinguished from weekly agents like semaglutide by monthly dosing.
ZX2021
ZX2021 (GGGF-1) is a Chinese Fc-fusion triple agonist of GCGR, GIPR, and GLP-1R by Jiangsu Zhongxin Pharmaceutical, in Phase 2 for obesity and type 2 diabetes.
ZYH7
ZYH7 (ZYH-7) is an investigational PPARα agonist for dyslipidemia developed by Zydus Cadila; IND filed 2007, phase 2 trial NCT01539616 versus fenofibrate completed.